Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts.

Drug Metabolism Reviews
Yasen MaimaitiyimingHua Naranmandura

Abstract

Arsenic trioxide (ATO) is one of the most effective drugs for treatment of acute promyelocytic leukemia (APL). It could specifically target the PML/RARα fusion oncoprotein stability and induces APL cell differentiation as well as apoptosis. Although many studies have been conducted to document the anticancer effects and mechanism of ATO, there is little information about the association between biotransformation of ATO to active arsenic metabolites and APL therapy. Generally, ATO can be rapidly converted into trivalent methylated metabolites by arsenic (+3 oxidation state) methyltransferase (AS3MT) mostly in liver and redistributed to bloodstream of APL patients who receiving ATO treatment, thereby leading to a balance between cytotoxicity and differentiation, which is proposed to be the key event in successful treatment of APL. In this review, we comprehensively discussed possible roles of AS3MT and methylated arsenic metabolites in APL therapy, so as to reveal the association between individual differences of AS3MT expression and activity with the therapeutic efficacy of ATO in APL patients.

References

Jan 1, 1997·Annual Review of Pharmacology and Toxicology·H V Aposhian
Dec 28, 1999·Proceedings of the National Academy of Sciences of the United States of America·J ZhuH de Thé
Dec 17, 2002·Chemical Research in Toxicology·Stephen NesnowMarc J Mass
May 25, 2004·The Journal of Biological Chemistry·Stéphane DesaintMichel B Toledano
May 26, 2004·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Helene PelicanoPeng Huang
Feb 3, 2006·Proceedings of the National Academy of Sciences of the United States of America·Jie QinChristopher Rensing
Aug 22, 2006·Chemical Research in Toxicology·Hua NaranmanduraKazuo T Suzuki
Jan 1, 2008·Journal of Inorganic Biochemistry·Kirk T Kitchin, Kathleen Wallace
Jul 1, 2009·Investigational New Drugs·Jennifer WuAndrew X Zhu
May 28, 2010·Autophagy·Michael DewaelePatrizia Agostinis
Jun 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elizabeth HousmanAnn Mullally
Mar 10, 2011·Toxicological Sciences : an Official Journal of the Society of Toxicology·Masanao YokohiraSamuel M Cohen
Jun 9, 2011·Chemical Research in Toxicology·Hua NaranmanduraNoriyuki Suzuki
Jul 7, 2011·International Journal of Molecular Sciences·Tetsuro AgusaHisato Iwata
Sep 21, 2011·Expert Review of Anticancer Therapy·Bayard L Powell
Nov 15, 2011·American Journal of Hematology·Peter J HoseinIzidore S Lossos
Feb 24, 2012·Metallomics : Integrated Biometal Science·Kanwal Rehman, Hua Naranmandura
Mar 20, 2012·Toxicology and Applied Pharmacology·Hua NaranmanduraNoriyuki Suzuki
Nov 6, 2012·Biological & Pharmaceutical Bulletin·Daigo Sumi, Seiichiro Himeno
Mar 20, 2013·The Journal of Experimental Medicine·Julien AblainHugues de Thé

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis